The Europe cell therapy market is projected to register a CAGR of 14.63% during the forecast period, 2022-2030, and is set to reach a revenue of $1990.50 million by 2030.

EUROPE CELL THERAPY MARKET FORECAST 2022-2030

Europe Cell Therapy Market by Cell Type (Stem Cell (Bone Marrow, Blood, Umbilical Cord-derived Stem Cell, Adipose-derived Stem Cell, Others), Non-stem Cell) Market by Therapy Type (Autologous, Allogeneic) Market by Therapeutic Application (Malignancies, Musculoskeletal Disorders, Autoimmune Disorders, Dermatology, Other Applications) Market by End-user (Hospitals & Clinics, Academic & Research Institutes) By Geography

Request free sample

The Europe cell therapy market is projected to register a CAGR of 14.63% during the forecast period, 2022-2030, and is set to reach a revenue of $1990.50 million by 2030.

The cell therapy market growth in Europe is attributed to the increasing research, rising investments in the development of regenerative medicines, and government initiatives that promote stem cell treatments. However, the Europe cell therapy market growth is restrained by long-term safety concerns and high costs.

Europe Cell Therapy Market

To know more about this report, request a free sample copy

The Europe cell therapy market growth analysis includes the assessment of the United Kingdom, Poland, Belgium, Germany, Spain, Italy, France, and Rest of Europe. In the United Kingdom, the regenerative medicine sector is projecting unprecedented growth. Around 2000 patients in the UK need stem cell or bone marrow transplants annually, as per the Anthony Nolan Foundation. Also, as per Blood Cancer UK, approximately 40,000 people are diagnosed with blood cancer every year, and almost 25,000 patients have blood cancer. Accordingly, bone marrow and stem cell replacement procedures increase the demand for cell therapies.

Further, regenerative medicine (RM) is evaluated as a promising area of science in the UK. Also, the number of advanced therapy medicinal product (ATMP) clinical trials is on a steady rise. For instance, there were more than 127 ongoing regenerative medicine clinical trials as of December 2019, according to Catapult UK. In addition, the increasing developments associated with RM within the UK are focused on a vast range of diseases that primarily target the eye, alongside neurological conditions, blood cancer, and bone & cartilage defects.

In Spain, the market growth is recording significant rates, given the increased funding for cell therapy research projects. Also, the growing investments and research activities in cancer-related projects to strengthen innovations offer growth opportunities. For instance, the partnership between the Spanish Association Against CANCER, the Italian Association for Cancer Research, and Cancer Research UK aims to accelerate translational research in drug resistance, immunotherapies, CAR-T cell production, and diagnostics at academic centers.

Additionally, strategic initiatives by international organizations promote the adoption of cell therapies. For instance, Global Stem Cells Group (GSCG) opened a new stem cell center in June 2019 in the country. Such factors drive the cell therapy market growth in these countries.

The Europe cell therapy market segmentation includes end-user, therapeutic application, therapy type, and cell type. The therapy type segment includes allogeneic and autologous.

Allogeneic therapies are produced in a large number of batches from irrelative donor tissues. They are made in large numbers to treat a large pool of patients. Accordingly, they must follow Good Manufacturing Practices (GMP) and hence are quality controlled. Also, manufacturers are prioritizing the development of regenerative therapies by emphasizing innovations.

In addition, several regenerative therapeutic applications have received approvals for clinical trials in Asia-Pacific, Europe, and the US due to the efficiency of allogeneic stem cell therapeutics. Furthermore, the approvals for clinical trials facilitate the launch of new product lines to accelerate the overall demand for stem therapy using allogenic stem cell therapeutics.

Some of the prominent market players operating in the Europe cell therapy market are Vericel Corporation, Stemedica Cell Technologies Inc, NuVasive Inc, Smith & Nephew Plc, etc.

Smith & Nephew Plc is a global medical devices business operating in the endoscopy, advanced wound management, and orthopedics markets. The company caters to procurement groups & patients, healthcare systems, payers & administrators, retail consumers, surgeons, etc. It has manufacturing facilities and distribution hubs in the Middle East & Africa, Asia-Pacific, North America, and Europe, with headquarters in London, the United Kingdom.

One of its key products, Bio4, is employed in bone repair at sites of bone damage in cell therapy for trauma, orthopedics, and spine surgeries.

Report Synopsis

Report ScopeDetails
Market Forecast Years2022-2030
Base Year2021
Market Historical Years2018-2021
Forecast UnitsRevenue ($ Million)
Segments AnalyzedEnd-User, Therapeutic Application, Therapy Type, Cell Type
Countries AnalyzedThe United Kingdom, Poland, Belgium, Germany, Spain, Italy, France, and Rest of Europe
Companies Analyzed

Anterogen Co Ltd, Bristol Myers Squibb Company, Cells for Cells SA, Gilead Sciences Inc, JCR Pharmaceuticals Co Ltd, Kolon TissueGene Inc, MEDIPOST Co Ltd, Mesoblast Limited, NuVasive Inc, Smith & Nephew Plc, Stemedica Cell Technologies Inc, Vericel Corporation

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      • KEY DRIVERS
        • INCREASING CELLULAR THERAPY CLINICAL TRIALS
        • GROWTH OF REGENERATIVE MEDICINE
        • HIGH PREVALENCE OF CHRONIC DISEASES
      • KEY RESTRAINTS
        • INCREASING SKILLS GAP
        • HIGH COSTS
    1. KEY ANALYTICS
      • IMPACT OF COVID-19 ON CELL THERAPY MARKET
      • KEY MARKET TRENDS
      • PORTER’S FIVE FORCES ANALYSIS
        • BUYERS POWER
        • SUPPLIERS POWER
        • SUBSTITUTION
        • NEW ENTRANTS
        • INDUSTRY RIVALRY
      • REGULATORY FRAMEWORK
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
    2. MARKET BY CELL TYPE
      • STEM CELL
        • BONE MARROW
        • BLOOD
        • UMBILICAL CORD-DERIVED STEM CELL
        • ADIPOSE-DERIVED STEM CELL
        • OTHERS
      • NON-STEM CELL
    3. MARKET BY THERAPY TYPE
      • AUTOLOGOUS
      • ALLOGENEIC
    4. MARKET BY THERAPEUTIC APPLICATION
      • MALIGNANCIES
      • MUSCULOSKELETAL DISORDERS
      • AUTOIMMUNE DISORDERS
      • DERMATOLOGY
      • OTHER APPLICATIONS
    5. MARKET BY END-USER
      • HOSPITALS & CLINICS
      • ACADEMIC & RESEARCH INSTITUTES
    6. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • MARKET SIZE & ESTIMATES
        • KEY DRIVERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • UNITED KINGDOM
          • GERMANY
          • FRANCE
          • ITALY
          • SPAIN
          • BELGIUM
          • POLAND
          • REST OF EUROPE
    1. COMPETITIVE LANDSCAPE
      • KEY STRATEGIC DEVELOPMENTS
        • MERGERS & ACQUISITIONS
        • PRODUCT LAUNCHES & DEVELOPMENTS
        • PARTNERSHIPS & AGREEMENTS
        • BUSINESS EXPANSIONS
      • COMPANY PROFILES
        • ANTEROGEN CO LTD
        • BRISTOL MYERS SQUIBB COMPANY
        • CELLS FOR CELLS SA
        • GILEAD SCIENCES INC
        • JCR PHARMACEUTICALS CO LTD
        • KOLON TISSUEGENE INC
        • MEDIPOST CO LTD
        • MESOBLAST LIMITED
        • NUVASIVE INC
        • SMITH & NEPHEW PLC
        • STEMEDICA CELL TECHNOLOGIES INC
        • VERICEL CORPORATION

    LIST OF TABLES

    TABLE 1: MARKET SNAPSHOT – CELL THERAPY

    TABLE 2: REGULATORY FRAMEWORK

    TABLE 3: EUROPE CELL THERAPY MARKET, BY CELL TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 4: EUROPE CELL THERAPY MARKET, BY CELL TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 5: EUROPE CELL THERAPY MARKET, BY STEM CELL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 6: EUROPE CELL THERAPY MARKET, BY STEM CELL, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 7: EUROPE CELL THERAPY MARKET, BY THERAPY TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 8: EUROPE CELL THERAPY MARKET, BY THERAPY TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 9: EUROPE CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 10: EUROPE CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 11: EUROPE CELL THERAPY MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 12: EUROPE CELL THERAPY MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 13: EUROPE CELL THERAPY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 14: EUROPE CELL THERAPY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 15: KEY PLAYERS IN EUROPE CELL THERAPY MARKET

    TABLE 16: LIST OF MERGERS & ACQUISITIONS

    TABLE 17: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

    TABLE 18: LIST OF PARTNERSHIPS & AGREEMENTS

    TABLE 19: LIST OF BUSINESS EXPANSIONS

    LIST OF FIGURES

    FIGURE 1: KEY MARKET TRENDS

    FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

    FIGURE 3: OPPORTUNITY MATRIX

    FIGURE 4: VENDOR LANDSCAPE

    FIGURE 5: EUROPE CELL THERAPY MARKET, GROWTH POTENTIAL, BY CELL TYPE, IN 2021

    FIGURE 6: EUROPE CELL THERAPY MARKET, BY STEM CELL, 2022-2030 (IN $ MILLION)

    FIGURE 7: EUROPE CELL THERAPY MARKET, GROWTH POTENTIAL, BY STEM CELL, IN 2021

    FIGURE 8: EUROPE CELL THERAPY MARKET, BY BONE MARROW, 2022-2030 (IN $ MILLION)

    FIGURE 9: EUROPE CELL THERAPY MARKET, BY BLOOD, 2022-2030 (IN $ MILLION)

    FIGURE 10: EUROPE CELL THERAPY MARKET, BY UMBILICAL CORD-DERIVED STEM CELL, 2022-2030 (IN $ MILLION)

    FIGURE 11: EUROPE CELL THERAPY MARKET, BY ADIPOSE-DERIVED STEM CELL, 2022-2030 (IN $ MILLION)

    FIGURE 12: EUROPE CELL THERAPY MARKET, BY OTHERS, 2022-2030 (IN $ MILLION)

    FIGURE 13: EUROPE CELL THERAPY MARKET, BY NON-STEM CELL, 2022-2030 (IN $ MILLION)

    FIGURE 14: EUROPE CELL THERAPY MARKET, GROWTH POTENTIAL, BY THERAPY TYPE, IN 2021

    FIGURE 15: EUROPE CELL THERAPY MARKET, BY AUTOLOGOUS, 2022-2030 (IN $ MILLION)

    FIGURE 16: EUROPE CELL THERAPY MARKET, BY ALLOGENEIC, 2022-2030 (IN $ MILLION)

    FIGURE 17: EUROPE CELL THERAPY MARKET, GROWTH POTENTIAL, BY THERAPEUTIC APPLICATION, IN 2021

    FIGURE 18: EUROPE CELL THERAPY MARKET, BY MALIGNANCIES, 2022-2030 (IN $ MILLION)

    FIGURE 19: EUROPE CELL THERAPY MARKET, BY MUSCULOSKELETAL DISORDERS, 2022-2030 (IN $ MILLION)

    FIGURE 20: EUROPE CELL THERAPY MARKET, BY AUTOIMMUNE DISORDERS, 2022-2030 (IN $ MILLION)

    FIGURE 21: EUROPE CELL THERAPY MARKET, BY DERMATOLOGY, 2022-2030 (IN $ MILLION)

    FIGURE 22: EUROPE CELL THERAPY MARKET, BY OTHER APPLICATIONS, 2022-2030 (IN $ MILLION)

    FIGURE 23: EUROPE CELL THERAPY MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021

    FIGURE 24: EUROPE CELL THERAPY MARKET, BY HOSPITALS & CLINICS, 2022-2030 (IN $ MILLION)

    FIGURE 25: EUROPE CELL THERAPY MARKET, BY ACADEMIC & RESEARCH INSTITUTES, 2022-2030 (IN $ MILLION)

    FIGURE 26: EUROPE CELL THERAPY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

    FIGURE 27: UNITED KINGDOM CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 28: GERMANY CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 29: FRANCE CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 30: ITALY CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 31: SPAIN CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 32: BELGIUM CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 33: POLAND CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 34: REST OF EUROPE CELL THERAPY MARKET, 2022-2030 (IN $ MILLION)       

    1. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • MARKET SIZE & ESTIMATES
        • KEY DRIVERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • UNITED KINGDOM
          • GERMANY
          • FRANCE
          • ITALY
          • SPAIN
          • BELGIUM
          • POLAND
          • REST OF EUROPE
    1. MARKET BY CELL TYPE
      • STEM CELL
        • BONE MARROW
        • BLOOD
        • UMBILICAL CORD-DERIVED STEM CELL
        • ADIPOSE-DERIVED STEM CELL
        • OTHERS
      • NON-STEM CELL
    2. MARKET BY THERAPY TYPE
      • AUTOLOGOUS
      • ALLOGENEIC
    3. MARKET BY THERAPEUTIC APPLICATION
      • MALIGNANCIES
      • MUSCULOSKELETAL DISORDERS
      • AUTOIMMUNE DISORDERS
      • DERMATOLOGY
      • OTHER APPLICATIONS
    4. MARKET BY END-USER
      • HOSPITALS & CLINICS
      • ACADEMIC & RESEARCH INSTITUTES

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type